It was a busy week for the biotech sector. While the fourth-quarter earnings season continues, other pipeline and regulatory ...

As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company ...

We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock investors bought 179,268 call options on the company. This represents an increase ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...

Market News Wall Street was closed on Monday for Presidents’ Day. U.S. stocks ended mixed on Friday due to strong earnings and economic data. While the Nasdaq rose, the Dow and the S&P 500 fell. How ...

Danaher, Recursion Pharmaceuticals, Moderna, Thermo Fisher Scientific, AbbVie, Vertex Pharmaceuticals, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to ...

In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna (MRNA – Research Report) on February 14 and set a price target of $45.00.